마이크로 RNA 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

MicroRNA Market Size, Share & Trends Analysis Report By Products & Services, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,728,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,195,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,129,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

마이크로 RNA 시장 요약

세계의 마이크로 RNA 시장 규모는 2024년에 17억 6,000만 달러로 추정되며, 2033년까지 54억 8,000만 달러에 이를 것으로 예측됩니다.

또한 2025년부터 2033년까지 연평균 복합 성장률(CAGR) 13.64%를 보일 것으로 예측됩니다. 전 세계적으로 암, 심혈관질환, 신경질환 등의 질병 유병률이 증가하고 있는 점과 유전체 기술의 발전이 가속화되고 있는 점이 시장 성장을 이끄는 주요 요인입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수와 동향

• 시장 동향 전망
  • 상위 시장 전망
  • 관련 시장 및 부수 시장 전망
• 시장 역학
• 업계 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석

제4장 제품 및 서비스 사업 분석

• 마이크로 RNA 시장 : 제품 및 서비스 변동 분석
• 제품
  • 제품 시장 추정·예측, 2021년-2033년
  • 기기
  • 소모품
• 서비스
  • 서비스 시장 추정·예측(2021년-2033년)
  • 서비스 유형별
  • 검체별

제5장 용도별 사업 분석

• 마이크로 RNA 시장 : 용도 변동 분석
• 암
  • 암 시장 매출 추정·예측, 2021년-2033년
• 감염증
  • 감염증 시장 매출 추산·예측, 2021년-2033년
• 면역 질환
  • 면역 질환 시장 매출 추산·예측, 2021년-2033년
• 심혈관 질환
  • 심혈관 질환 시장 매출 추산·예측, 2021년-2033년
• 신경 질환
  • 신경 질환 시장 매출 추산·예측, 2021년-2033년
• 기타
  • 기타 시장 시장 매출 추산·예측(2021년-2033년)

제6장 최종 용도별 비즈니스 분석

• 마이크로 RNA 시장 : 최종 용도 변동 분석
• 바이오테크놀러지 및 제약 기업
  • 바이오테크놀러지 및 제약 기업 시장 시장 매출 추산과 예측(2021년-2033년)
• 학술 및 정부 연구기관
  • 학술 및 정부 연구기관 시장 매출 추산·예측(2021년-2033년)
• 기타 최종사용자
  • 기타 최종사용자 시장 시장 매출 추산·예측(2021년-2033년)

제7장 지역별 사업 분석

• 지역별 마이크로 RNA 시장 점유율(2024년 및 2033년)
• 북미
  • 북미 마이크로 RNA 시장, 2021년-2033년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽 마이크로 RNA 시장, 2021년-2033년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양 마이크로 RNA 시장, 2021년-2033년
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카 마이크로 RNA 시장, 2021년-2033년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카 마이크로 RNA 시장, 2021년-2033년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업 시장 현황 분석(2024년)
• 기업 개요/리스트
  • Thermo Fisher Scientific
  • QIAGEN
  • Horizon Discovery Group plc.
  • Merck KGaA
  • Takara Bio, Inc.
  • LGC Limited
  • BioGenex
  • GeneCopoeia, Inc.
  • New England Biolabs
  • NanoString Technologies, Inc.

LSH

영문 목차

영문목차

MicroRNA Market Summary

The global microRNA market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.48 billion by 2033, growing at a CAGR of 13.64% from 2025 to 2033. The increasing prevalence of diseases such as cancer, cardiovascular diseases, and neurological disorders across the globe, as well as growing advancements in genomic technologies, are the prime factors that drive market growth.

Global MicroRNA Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global microRNA market on the basis of product & service, application, end-use, and region:

• Product & Services Outlook (Revenue in USD Million, 2021- 2033)
• Services
  • Type
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis
  • Others
  • Specimen
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others
• Products
  • Instruments
  • Technology
  • Real Time PCR
  • Microarray
  • NGS
  • Others
  • Workflow
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis & Others
  • Others
  • Consumables
  • Specimens
  • Whole Blood
  • Serum
  • Plasma
  • FFPE
  • Fresh Frozen Tissue
  • Others
  • Workflow
  • Isolation & Purification
  • miRNA cDNA Synthesis
  • Profiling, Localization, & Quantification
  • Functional Analysis
  • Others
• Application Outlook (Revenue, USD Million, 2021- 2033)
• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others
• End-use Outlook (Revenue, USD Million; 2021 - 2033)
• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expanding use of miRNA in drug development & therapeutics
    • 3.2.1.2. Increasing cancer prevalence and need for early-stage diagnostics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost associated with microRNA kits and other products
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product & Service Business Analysis

• 4.1. Segment Dashboard
• 4.2. MicroRNA Market: Product & Service Movement Analysis
• 4.3. Product
  • 4.3.1. Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Instruments
    • 4.3.2.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.2. By Technology
      • 4.3.2.2.1. Real-Time PCR
        • 4.3.2.2.1.1. Real-Time PCR Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.2.2. Microarray
        • 4.3.2.2.2.1. Microarray Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.2.3. NGS
        • 4.3.2.2.3.1. NGS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.2.4. Others
        • 4.3.2.2.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.3. By Workflow
      • 4.3.2.3.1. Isolation & Purification
        • 4.3.2.3.1.1. Isolation & Purification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3.2. miRNA cDNA Synthesis
        • 4.3.2.3.2.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3.3. Profiling, Localization, & Qualification
        • 4.3.2.3.3.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3.4. Functional Analysis & Others
        • 4.3.2.3.4.1. Functional Analysis & Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3.5. Others
        • 4.3.2.3.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Consumables
    • 4.3.3.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.2. By Specimen
      • 4.3.3.2.1. Whole Blood
        • 4.3.3.2.1.1. Whole Blood Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.2. Serum
        • 4.3.3.2.2.1. Serum Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.3. Plasma
        • 4.3.3.2.3.1. Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.4. FFPE
        • 4.3.3.2.4.1. FFPE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.5. Fresh Frozen Tissue
        • 4.3.3.2.5.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2.6. Others
        • 4.3.3.2.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.3. By Workflow
      • 4.3.3.3.1. Isolation & Purification
        • 4.3.3.3.1.1. Isolation & Purification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3.2. miRNA cDNA Synthesis
        • 4.3.3.3.2.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3.3. Profiling, Localization, & Qualification
        • 4.3.3.3.3.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3.4. Functional Analysis & Others
        • 4.3.3.3.4.1. Functional Analysis & Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3.5. Others
        • 4.3.3.3.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Services
  • 4.4.1. Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. By Service Type
    • 4.4.2.1. Isolation & Purification
      • 4.4.2.1.1. Isolation & Purification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.2. miRNA cDNA Synthesis
      • 4.4.2.2.1. miRNA cDNA Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.3. Profiling, Localization, & Qualification
      • 4.4.2.3.1. Profiling, Localization, & Qualification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.4. Functional Analysis
      • 4.4.2.4.1. Functional Analysis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.5. Others
      • 4.4.2.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. By Specimen
    • 4.4.3.1. Whole Blood
      • 4.4.3.1.1. Whole Blood Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.2. Serum
      • 4.4.3.2.1. Serum Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.3. Plasma
      • 4.4.3.3.1. Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.4. FFPE
      • 4.4.3.4.1. FFPE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.5. Fresh Frozen Tissue
      • 4.4.3.5.1. Fresh Frozen Tissue Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.6. Others
      • 4.4.3.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Segment Dashboard
• 5.2. MicroRNA Market: Application Movement Analysis
• 5.3. Cancer
  • 5.3.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Infectious Diseases
  • 5.4.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Immunological Disorder
  • 5.5.1. Immunological Disorder Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Cardiovascular Disease
  • 5.6.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Neurological Disease
  • 5.7.1. Neurological Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. Segment Dashboard
• 6.2. MicroRNA Market: End Use Movement Analysis
• 6.3. Biotechnology & Pharmaceutical Companies
  • 6.3.1. Biotechnology & Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Academic & Government Research Institutes
  • 6.4.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Other End-users
  • 6.5.1. Other End-users Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. MicroRNA Market Share By Region, 2024 & 2033
• 7.2. North America
  • 7.2.1. North America MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Regulatory framework
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. U.S. MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Regulatory framework
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Canada MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Regulatory framework
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Mexico MicroRNA Market, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. UK MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Germany MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. France MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Regulatory framework
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Italy MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Regulatory framework
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Spain MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Regulatory framework
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Denmark MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Regulatory framework
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Sweden MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Regulatory framework
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Norway MicroRNA Market, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Japan MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. China MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. India MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Australia MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Thailand MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. South Korea MicroRNA Market, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Brazil MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Argentina MicroRNA Market, 2021 - 2033 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. South Africa MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Saudi Arabia MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. UAE MicroRNA Market, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Kuwait MicroRNA Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. QIAGEN
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Horizon Discovery Group plc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Merck KGaA
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Takara Bio, Inc.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. LGC Limited
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. BioGenex
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. GeneCopoeia, Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. New England Biolabs
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. NanoString Technologies, Inc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives

관련자료